Editor's Correspondence |

Trimethoprim-Sulfamethoxazole–Induced Life-Threatening Agranulocytosis—Reply

Philip A. Masters, MD; Thomas A. O'Bryan, MD; John Zurlo, MD; Debra Q. Miller, MD; Nirmal Joshi, MD
Arch Intern Med. 2003;163(16):1975-1976. doi:10.1001/archinte.163.16.1975.
Text Size: A A A
Published online


In reply

Andrès and colleagues raise the issue of the significance of hematological toxicity, particularly agranulocytosis, associated with the use of TMP-SMZ. As noted in our review,1 a number of hematological adverse reactions have been attributed to the antibiotic combination, although the exact frequency with which such toxic effects occur is difficult to determine. The data presented by Andrès et al2 cite an annual incidence of nonchemotherapy drug-induced agranulocytosis for all medications to be in the range of 3 to 10 cases per million, with approximately 10% of cases in their 91-patient prospective study over 15 years associated specifically with TMP-SMZ use, suggesting a very low absolute risk of life-threatening agranulocytosis associated with the use of this medication. Clinically significant hematological effects, including agranulocytosis, associated with the use of TMP-SMZ have also not precluded its use specifically for prophylaxis against infections in neutropenic patients.3

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles